Takeda to make $200m loss after Novartis' dry-eye drug hits ...

Novartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing it to make a loss of $200 million this quarter. 

Takeda posts surprise profit a year after Shire mega-merger

Japan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year ago, as the company shakes off the huge debts it incurred to get the deal done. 

Breadth versus depth in R&D management

Takeda’s Georgia Keresty is one of the only chief operating officers (COOs) for R&D in the industry.

2019: the year of the pharma mega-merger

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year that changed the landscape of big pharma

Takeda eyes emerging markets asset sale to trim its debt; re...

Case Study: How Shire improved its time-to-market

Adopting an end-to-end commercial content management system has allowed one of the world’s biggest pharmaceutical companies to be quicker, more efficient and more compliant.